硫普罗宁联合匹格列酮在治疗非酒精性脂肪性肝病中的疗效评价  

The Curative Effect Evaluation of Tiopronin Combined With Pioglitazone on Non-alcoholic Fatty Liver Disease

作　　者：蔡玲伟 

机构地区：[1]河南省漯河市第二人民医院内科,462000

出　　处：《中国继续医学教育》2015年第17期141-142,共2页China Continuing Medical Education

摘　　要：目的评估硫普罗宁联合匹格列酮在治疗非酒精性脂肪肝病的临床疗效。方法选取我院收治的60例非酒精性脂肪性肝病患者,随机分成对照组30例,治疗组30例。对照组予饮食运动综合治疗,治疗组在综合治疗基础上给予硫普罗宁肠溶片20 mg,3次/日口服,并联合匹格列酮30 mg,1次/d早餐前口服治疗,疗程6个月,观察治疗前后患者临床症状、肝功能变化情况。结果与对照组相比,治疗组临床表现与肝功能有明显改善,肝功能改变两组相比,差异有统计学意义(P<0.05)。结论硫普罗宁联合匹格列酮在治疗治疗非酒精性脂肪肝病中,可以使临床症状与肝功能显著改善,疗效显著。Objective To evaluate the clinical effect of tiopronin combined with pioglitazone on non-alcoholic fatty liver disease.Methods A total of 60 casesof non-alcoholic fatty liver diseasein my hospital were randomly divided intocontrol group and treatment group with 30 cases pergroup.The control group received combined therapy,while the treatment group was treated with orally taken with tiopronin 20 mg,3/d,and pioglitazone 30 mg before breakfast besides the combined therapy,for 6 months.Clinical symptoms,liver function changes of the patients were observed before and after treatment.Results Compared with control group,clinical manifestation and liver function were improved in treatment group.The liver function changes in two groups,the difference was statistically significant（P〈0.05）.Conclusion Tiopronin combined with pioglitazone can significantly improve clinical symptoms and liver function of non-alcoholic fatty liver disease,curative effect is distinct.

关 键 词：硫普罗宁 匹格列酮 非酒精性脂肪性肝病 

分 类 号：R575[医药卫生—消化系统]